Literature DB >> 1942327

Computerized tomography for detection and staging of localized and pathologically defined upper tract urothelial tumors.

J G McCoy1, H Honda, M Reznicek, R D Williams.   

Abstract

Between 1980 and 1989, 94 patients were evaluated for upper tract urothelial tumors. Preoperative computerized tomography (CT) scans and pathology reports were available in 30 patients who also had nephroureterectomy for treatment of transitional cell carcinoma. Retrospective evaluation of these CT scans was done without knowledge of the final pathological status to determine accuracy of tumor detection and staging. Pathological findings were also reviewed and the pathological staging was compared to that of CT. At pathological evaluation the 30 renal units contained 34 grossly visible, distinct papillary tumors: 7 were ureteral and 27 were in the renal pelvis. Of the renal units 8 also contained carcinoma in situ that was not visible on any study. Conventional excretory urograms and/or retrograde or antegrade pyelograms detected 28 (82%) and CT 17 (50%) of the 34 papillary tumors. Excluding suboptimal scans due to early generation machines, inadequate intravenous contrast medium or too widely spaced slices caused CT sensitivity to increase to 15 of 22 (68%). It was not possible to distinguish stages Ta to T2 lesions on any radiological study. CT sensitivity for parenchymal invasion was 75% with a specificity of 43%. CT sensitivity for fat invasion was 67% with a specificity of 44%. We conclude that CT is limited in usefulness for detection and staging of low stage upper tract urothelial tumors. While CT is the best current imaging modality over-all for staging of upper tract urothelial tumors, results obtained in low stage tumors must be viewed with caution particularly when precise preoperative clinical staging is essential, such as before nephron-sparing procedures.

Entities:  

Mesh:

Year:  1991        PMID: 1942327     DOI: 10.1016/s0022-5347(17)38150-8

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

1.  Standardized ex vivo comparison of different upper urinary tract biopsy devices: impact on ureterorenoscopes and tissue quality.

Authors:  M Ritter; C Bolenz; T Bach; P Ströbel; A Häcker
Journal:  World J Urol       Date:  2012-03-27       Impact factor: 4.226

2.  Association between lymph node yield and survival among patients undergoing radical nephroureterectomy for urothelial carcinoma of the upper tract.

Authors:  Piotr Zareba; Barak Rosenzweig; Andrew G Winer; Jonathan A Coleman
Journal:  Cancer       Date:  2017-02-02       Impact factor: 6.860

3.  [Indications for intravenous urography].

Authors:  C Schleicher; R Neumann; W A Kaiser; G Stein
Journal:  Med Klin (Munich)       Date:  1997-02-15

4.  Multidetector-row computed tomography (MDCT) in patients with a history of previous urothelial cancer or painless macroscopic haematuria.

Authors:  Ullrich G Mueller-Lisse; Ulrike L Mueller-Lisse; Josef Hinterberger; Peter Schneede; Thomas Meindl; Maximilian F Reiser
Journal:  Eur Radiol       Date:  2007-04-03       Impact factor: 5.315

5.  Multiphasic multidetector-row CT (MDCT) in detection and staging of transitional cell carcinomas of the upper urinary tract.

Authors:  Gerald A Fritz; Helmut Schoellnast; Hannes A Deutschmann; Franz Quehenberger; Manfred Tillich
Journal:  Eur Radiol       Date:  2006-01-11       Impact factor: 5.315

6.  Nephroureterectomy for transitional cell carcinoma - the value of pre-operative histology.

Authors:  Sudhanshu Chitale; Rashidi Mbakada; Stuart Irving; Neil Burgess
Journal:  Ann R Coll Surg Engl       Date:  2008-01       Impact factor: 1.891

7.  Postoperative distal ureteric and bladder cuff recurrence in a Grade I renal transitional cell carcinoma diagnosed and restaged by fluorodeoxyglucose positron emission tomography-computed tomography.

Authors:  Sunita Sonavane; Deepa Rani; Ramesh Asopa; Trupti Upadhye; Dilip Pawar
Journal:  Indian J Nucl Med       Date:  2014-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.